Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. University of Virginia, Charlottesville, VA, United States

Survival: 6.2 months
Toxicity Grade: 4
Treatments: Immunotherapy
Country: United States
City/State/Province: Charlottesville, VA
Hospital: University of Virginia
Journal: Link
Date: 11/2003

Patients: This Phase II study involved 26 patients with advanced melanoma. Patients were divided into two groups of 13 patients each - Group A and Group B. There were 6 men and 7 women in Group A and 10 men and 3 women in Group B. The median age of patients in Group A was 57 and the median age of patients in Group B was 49.

Treatment: The treatment for patients in Group A consisted of a kind of immunotherapy - vaccination with four melanoma peptides pulsed on monocyte-derived dendridic cells.

Toxicity: Grade 3 -4 toxicities for patients in Groups A and B combined included malaise or fatigue, rash, diarrhea, dyspnea, nonlocal pain, metabolic or laboratory toxicity, endocrine, and acute vascular leak syndrome.

Results: The overal median survival for patients in Group A was 6.2 months.

Support: The study was supported in part by Schering-Plough.

Correspondence: Craig L. Slingluff, Jr., MD

E-mail to a Friend Email Physician More Information